Erlonat 150 Tablets

Erlonat 150 Tablets Specification

Origin
India

Salt Composition
Erlotinib Hydrochloride 150 mg

Indication
Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer

Dosage Form
Capsule

Enzyme Types
Ribasure 200 mg Capsule

Feature
Orally administered, targeted therapy, prescription only

Application
Oncology/Anti-Cancer Therapy

Physical Color/Texture
White to off-white, film-coated tablet

Fermentation Smell
Odorless (Pharmaceutical tablet)

Storage Instructions
Cool & Dry Place

Shelf Life
24 Months

Drug Class
Tyrosine Kinase Inhibitor

Strength
150 mg per tablet

Packaging Type
Box packing, Strip of 30 tablets

ATC Code
L01EB02

Administration Route
Oral

Warning
Use under medical supervision only

Container Material
Blister strips

Prescription/Non Prescription
Prescription Required

Erlonat 150 Tablets Trade Information

Minimum Order Quantity
5000 Pieces

Supply Ability
100 Pieces Per Day

Delivery Time
3-4 Days

Main Export Market(s)
Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa

Main Domestic Market
All India

About Erlonat 150 Tablets

Erlonat 150mg tablet is used in the treatment of pancreatic cancer and small cell lung cancer. In patients with cancer, a change in DNA (genetic material) triggers a signal which produces abnormal cancer cells. Erlonat 150mg tablet blocks this signal, and thus stops the production of these cancer cells

Targeted Oral Therapy for Cancer

Erlonat 150 Tablets provide a modern approach to cancer treatment by acting as a targeted therapy, inhibiting the action of tyrosine kinases involved in tumor growth. Their oral administration offers convenience for patients undergoing long-term cancer management.

Carefully Formulated and Packaged

Manufactured in India, Erlonat 150 is supplied in sturdy blister strips to protect the tablets from moisture and environmental factors. Each box contains 30 tablets, ensuring accurate dispensing and storage for maintaining efficacy throughout its 24-month shelf life.

FAQ's of Erlonat 150 Tablets:

Q: How should Erlonat 150 Tablets be administered?

A: Erlonat 150 Tablets are intended for oral use and should be swallowed whole with water, preferably on an empty stomach or as directed by your oncologist. Follow your doctor's precise dosage instructions for optimal results.

Q: What is Erlonat 150 primarily used for?

A: Erlonat 150 is mainly prescribed for non-small cell lung cancer (NSCLC) and pancreatic cancer. Its active ingredient, Erlotinib Hydrochloride, acts by inhibiting tyrosine kinase enzymes that promote cancer cell growth.

Q: When is a prescription required for Erlonat 150 Tablets?

A: A valid medical prescription is required to obtain Erlonat 150 Tablets. The medication should only be used under the strict supervision of a qualified healthcare professional.

Q: Where should Erlonat 150 Tablets be stored?

A: Keep the tablets in their original blister strips and box, stored in a cool and dry place, away from direct sunlight and moisture. Proper storage ensures their potency over their 24-month shelf life.

Q: What are the benefits of Erlonat 150 as a targeted therapy?

A: Erlonat 150 provides a targeted method to inhibit cancer growth by blocking specific enzymes rather than affecting a wide range of cells, potentially reducing side effects compared to conventional chemotherapy.

Q: What should be considered before starting Erlonat 150 Tablets?

A: Before beginning treatment, discuss your full medical history, current medications, and potential allergies with your doctor. Use Erlonat 150 strictly under professional medical supervision to minimize risks and monitor for adverse effects.

Q: Can Erlonat 150 Tablets be used for conditions other than cancer?

A: Erlonat 150 is specifically indicated for the treatment of NSCLC and pancreatic cancer and should not be used for other conditions unless recommended by a qualified healthcare provider.

Tell us about your requirement